Novartis' Jakavi bests current therapy for GvHD

23rd April 2020 Uncategorised 0

REACH2 is the first Phase III study in steroid-refractory acute graft-versus-host-disease (GvHD) to have met its primary endpoint

More: Novartis' Jakavi bests current therapy for GvHD
Source: News